CTOs on the Move

Liquidia Technologies

www.liquidia.com

 
Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.liquidia.com
  • PO Box 110085
    Research Triangle Park, NC USA 27709
  • Phone: 919.328.4400

Executives

Name Title Contact Details

Funding

Liquidia Technologies raised $22.4M on 12/26/2019

Similar Companies

OncoSec Medical

OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical’s core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s clinical programs currently include three Phase 2 trials targeting metastatic melanoma Merkel cell carcinoma and cutaneous T-cell lymphoma conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in these indications it is also investigating additional indications and combination therapeutic approaches.  

Nventa Biopharmaceuticals Corporation

Nventa Biopharmaceuticals Corporation is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BIND Biosciences

BIND Biosciences, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioSearch

BioSearch is a Falls Church, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SwanBio Therapeutics

With offices in Philadephia and Boston, SwanBio Therapeutics is developing leading-edge therapies to deliver dramatic clinical efficacy for the treatment of neurological diseases. We are driven by an unrelenting passion to solve difficult challenges, and a belief that meaningful discovery is borne of curiosity, collaboration, and compassion. Founded by proven industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialization expertise.